reverse merger

Lifeline
Biotech

After failed acquisition, Lisata finds lifeline in Marea merger

Alongside the stock-for-stock transaction that is bringing Lisata and Marea together, Lisata also announced a $225 million private placement.
Darren Incorvaia Sep 17, 2026 10:00am
public companies

Atopic dermatitis biotech heads to Nasdaq via reverse merger

Sep 17, 2026 7:40am
A wolf that looks sad

Werewolf transforms into Ambros via reverse merger

Aug 21, 2026 9:50am
two arrows pointing different directions

Slate uses Fulcrum to join Nasdaq with $245M for migraine trials

Aug 17, 2026 9:30am
two arrows pointing different directions

Caldera hits Nasdaq via Synlogic reverse merger

Jul 29, 2026 8:56am
water forest

Scancell heads to Nasdaq via reverse merger with Neuphoria

Jul 23, 2026 10:13am